ITP Values

  • by: |
  • 11/23/2011

Excellent article in the always excellent RX Compliance Report on the Europe’s continuing debate over the dissemination of healthcare information.

European Commission proposal on patient information draws divergent views

The European Commission’s (EC) revised proposals on information to patients, released last month, drew divergent assessments across the Atlantic. The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents research-based pharma companies operating in Europe, cautiously welcomed the amendments, urging all member states to adopt a “pragmatic approach” to address what it calls “the existing inequality” of access to quality data. “The revised proposals put rights, interests and safety of patients first,” insisted John Dalli, European Commissioner for health and consumer policy.

However, former FDA Commissioner for External Relations, Peter Pitts, spoke for many on this side of the Atlantic when he said the proposals appear to slow what had been a movement on the part of the EC to liberalize the industry’s ability to provide information about prescription drugs to patients. “That effort was on the ‘slow track’ before last month’s announcement,” says Pitts, who heads the Center for Medicine in the Public Interest in New York. “Now it’s on the ‘super slow track.”

International compliance expert, Paul Woods, says he is hopeful that the revised proposal will eventually be enacted in a form that will enable citizens all across Europe to have equal access to high quality non-promotional information about their prescription medicines. “The outcome, however, remains uncertain,” he says.

The complete RX Compliance Report article can be found here.

And a happy Thanksgiving to all.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog